Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 3, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 1-4, 2021 June 3, 2021 , 2:30 p.m.
View HTML
Toggle Summary Arrowhead Earns $10 Million Option Exercise Fee
PASADENA, Calif. --(BUSINESS WIRE)--May 18, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc. , (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered written notice of its intent to exercise its option right
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2021 RBC Capital Markets Global Healthcare – May 18-20, 2021 May 18, 2021 , 11:30 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
Conference Call and Webcast Today, May 4, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021 . The company is hosting a conference call today, May
View HTML
Toggle Summary Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 16, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021 .
View HTML
Toggle Summary Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM ) platform.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi)
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
Conference Call and Webcast Today, February 4 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2020 . The company is hosting a conference call at 4:30
View HTML